Kymera Therapeutics operates in the targeted protein degradation (TPD) space, aiming to eliminate disease-causing proteins rather than temporarily inhibiting their function. The company's clinical pipeline includes programs targeting IRAK4, STAT6, and IRF5 for immunological and inflammatory diseases, as well as MDM2 and CDK2 for oncology indications. Kymera has established strategic collaborations with major pharmaceutical companies, including Sanofi and Gilead Sciences, to support the clinical development and commercialization of its candidates. Its lead programs, such as the STAT6 degrader KT-621 and the IRAK4 degrader KT-474, are designed as oral therapies for conditions like atopic dermatitis and asthma. As a clinical-stage entity, the company does not yet have commercialized products and generates revenue primarily through upfront payments, research funding, and milestone payments from its partnerships.
